对特应性皮炎模拟定价及获取建议的批判性审视
A Critical Examination of Simulation Pricing and Access Recommendations for Atopic Dermatitis.
作者信息
Langley Paul C
机构信息
College of Pharmacy, University of Minnesota.
出版信息
Innov Pharm. 2021 Sep 22;12(4). doi: 10.24926/iip.v12i4.4329. eCollection 2021.
Abstract
It has been demonstrated conclusively that value and utility preference scores have only ordinal properties. This means, as has been pointed out on numerous occasions, that the quality adjusted life year (QALY) is a mathematically impossible construct. The implications are profound: Some 30 years of health technology assessment is called into question due to a failure to recognize the well-documented limitations imposed by the axioms of fundamental measurement. The purpose of this commentary is provide a critical examination of this practice in recommendations for atopic dermatitis.
摘要
已经确凿地证明，价值和效用偏好分数仅具有序数属性。正如在许多场合所指出的，这意味着质量调整生命年（QALY）在数学上是一个不可能的概念。其影响是深远的：由于未能认识到基本测量公理所带来的有充分记录的局限性，约30年的卫生技术评估受到质疑。本评论的目的是对特应性皮炎建议中的这种做法进行批判性审视。
相似文献
1
A Critical Examination of Simulation Pricing and Access Recommendations for Atopic Dermatitis.对特应性皮炎模拟定价及获取建议的批判性审视
Innov Pharm. 2021 Sep 22;12(4). doi: 10.24926/iip.v12i4.4329. eCollection 2021.
2
A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis.重症肌无力中依库珠单抗和艾加莫德定价的批判性审视
Innov Pharm. 2021 Sep 22;12(4). doi: 10.24926/iip.v12i4.4390. eCollection 2021.
3
The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER).“不可能的质量调整生命年”与对基本测量的否定：代表临床与经济评论学会（ICER）驳回华盛顿大学对溃疡性结肠炎中靶向免疫调节剂（TIMS）的价值评估
Innov Pharm. 2020 Jul 31;11(3). doi: 10.24926/iip.v11i3.3330. eCollection 2020.
4
Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing Claims.医疗补助药品处方集决策与临床和经济评论学会：摒弃虚拟药品定价索赔中的伪科学
Innov Pharm. 2021 Feb 16;12(1). doi: 10.24926/iip.v12i1.3702. eCollection 2021.
5
Nonsense on Stilts - Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds.《踩着高跷的胡言乱语——第一部分：2020 - 2023年ICER构建想象世界的价值评估框架》
Innov Pharm. 2020 Feb 14;11(1). doi: 10.24926/iip.v11i1.2444. eCollection 2020.
6
More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review's Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis.更多不必要的虚构世界——第1部分：临床与经济评论研究所关于类风湿关节炎中 Janus 激酶（JAK）抑制剂的证据报告
Innov Pharm. 2020 Jan 24;11(1). doi: 10.24926/iip.v11i1.2402. eCollection 2020.
7
To Dream the Impossible Dream: The Commitment by the Institute for Clinical and Economic Review to Rewrite the Axioms of Fundamental Measurement for Hemophilia A and Bladder Cancer Value Claims.去做那不可能实现的梦：临床与经济评论研究所为重写血友病A和膀胱癌价值声明基本衡量准则所做的承诺。
Innov Pharm. 2020 Dec 10;11(4). doi: 10.24926/iip.v11i4.3585. eCollection 2020.
8
More Unnecessary Imaginary Worlds - Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease.更多不必要的虚构世界 - 第4部分：镰状细胞病的crizanlizumab、voxelotor和L-谷氨酰胺的ICER证据报告
Innov Pharm. 2020 Apr 30;11(2). doi: 10.24926/iip.v11i2.3123. eCollection 2020.
9
Post-Menopausal Quality of Life Claims: Overlooking the Requirements of Normal Science and Fundamental Measurement in ICER'S Cost-Effectiveness Assessment of Fezolinetant for Moderate to Severe Vasomotor Symptoms.绝经后生活质量声明：在ICER对非唑奈坦治疗中度至重度血管舒缩症状的成本效益评估中忽视了常规科学和基本测量的要求。
Innov Pharm. 2023 Oct 10;14(1). doi: 10.24926/iip.v14i1.5118. eCollection 2023.
10
Yet another Ersatz World: The ICER Final Evidence Report for Additive Cardiovascular Therapies.另一个虚拟世界：心血管辅助治疗的ICER最终证据报告。
Innov Pharm. 2019 Oct 31;10(4). doi: 10.24926/iip.v10i4.2337. eCollection 2019.
本文引用的文献
1
Abandoning Eugenics and the QALY.摒弃优生学与质量调整生命年
Innov Pharm. 2021 Jun 10;12(3). doi: 10.24926/iip.v12i3.4291. eCollection 2021.
2
JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value.JAK 抑制剂和单克隆抗体治疗特应性皮炎：有效性和价值。
J Manag Care Spec Pharm. 2022 Jan;28(1):108-114. doi: 10.18553/jmcp.2022.28.1.108.
3
Peter Rabbit is a Badger in Disguise: Deconstructing the Belief System of the Institute for Clinical and Economic Review in Health Technology Assessment.彼得兔是一只伪装成獾的兔子：解构临床与经济评论研究所卫生技术评估中的信念体系。
Innov Pharm. 2021 May 25;12(2). doi: 10.24926/iip.v12i2.3992. eCollection 2021.
4
Fundamental Outcome Measurement: Selecting Patient Reported Outcome Instruments and Interpreting the Data they Produce.基本结局测量：选择患者报告结局工具并解读其产生的数据。
Innov Pharm. 2021 May 11;12(2). doi: 10.24926/iip.v12i2.3911. eCollection 2021.
5
Fundamental Measurement: The Need Fulfilment Quality of Life (N-QOL) Measure.基本测量：需求满足生活质量（N-QOL）测量
Innov Pharm. 2021 May 11;12(2). doi: 10.24926/iip.v12i2.3798. eCollection 2021.
6
Let a Thousand Models Bloom: ICER Analytics Opens the Floodgates to Cloud Pseudoscience.让千种模型竞相绽放：ICER 分析为云伪科学打开了闸门。
Innov Pharm. 2021 Jan 20;12(1). doi: 10.24926/iip.v12i1.3606. eCollection 2021.
7
The Great I-QALY Disaster.伟大的质量调整生命年灾难。
Innov Pharm. 2020 Jul 31;11(3). doi: 10.24926/iip.v11i3.3359. eCollection 2020.
8
Measurement, modeling and QALYs.测量、建模和 QALYs。
F1000Res. 2020 Aug 26;9:1048. doi: 10.12688/f1000research.25039.1. eCollection 2020.
9
Composite outcome measurement in clinical research: the triumph of illusion over reality?临床研究中的复合结局测量：是幻想战胜了现实吗？
J Med Econ. 2020 Oct;23(10):1196-1204. doi: 10.1080/13696998.2020.1797755. Epub 2020 Jul 29.
10
Higher self-reported severity of atopic dermatitis in adults is associated with poorer self-reported health-related quality of life in France, Germany, the U.K. and the U.S.A.在法国、德国、英国和美国，成年人自我报告的特应性皮炎严重程度越高，其自我报告的与健康相关的生活质量就越差。
Br J Dermatol. 2020 May;182(5):1176-1183. doi: 10.1111/bjd.18451. Epub 2019 Oct 28.
Zotero 插件